newsfilter
← Latest News
GlobeNewswire·

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

  • The U.S. FDA has approved Obagi saypha ChIQ injectable hyaluronic acid gel, a new addition to the Obagi Medical portfolio under Waldencast plc.
  • This approval follows the January 2026 launch of Obagi saypha MagIQ & supports the strategy to establish Obagi as a comprehensive leader in skincare & medical aesthetics.
  • Obagi saypha ChIQ utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix for natural-looking results with predictable injection profiles.
  • The product is indicated for cheek augmentation & correction of midface contour deficiencies in patients over age 21.
  • The ALOHA Program, launched in January 2026, serves as the largest real-world evaluation of a new HA filler to date & reports 94% of injectors believe MagIQ complements current options.
  • Interim ALOHA data indicates 42.6% of practices using Obagi saypha MagIQ have evaluated Obagi skincare, driving attachment rates significantly above the industry norm.
  • Croma-Pharma GmbH developed the product & reported producing over 130 million syringes globally by 2026.
  • Croma-Pharma is re-entering the orthopedics market in 2026 while maintaining its position as a leading European HA manufacturer.